Samsung Biologics (KRX:207940), a South Korea-based contract development and manufacturing organisation (CDMO), said on Thursday that it received recognition at the 2026 CDMO Leadership Awards presented by Outsourced Pharma and Life Science Connect.
The company was awarded the Sustainability Leadership Award, a jury-selected distinction recognising efforts to advance sustainable practices across its operations and value chain. Samsung Biologics was also named 'Best in Class' in Cultural Fit in the 'Biologics--Large CDMOs' category.
The CDMO Leadership Awards aim to recognise top-performing development and manufacturing service providers based on global client feedback across areas such as facilities, innovation, technical expertise, and manufacturing capabilities.
Sensei Biotherapeutics changes name to Faeth Therapeutics
Datavault AI and Wellgistics Health plan DelivMeds AI healthcare venture
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Atrium Therapeutics announces inducement grants to seven new employees
GXO appointed to manage NHS England bowel cancer home testing kits